$3.25B Tysabri Deal a Win-Win for Biogen Idec, ElanHome Topics Drug Discovery $3.25B Tysabri Deal a Win-Win for Biogen Idec, Elan Biogen Idec’s $3.25 billion-plus-royalties purchase of all rights to Tysabri (natalizumab), the multiple sclerosis drug it co-developed with Elan, boosts Biogen Idec’s presence in MS drugs while leaving the Irish-owned biotech in the enviable position of having control of its future, and some spending cash to boot, afte
Biogen Idec Explains Company’s Move Away from Venture Funding | GEN
